CJC-1295: Mechanism and Research Overview

Reviewed by Dr. James Harlow, MD, Sports Medicine
Topics: GH Peptides
CJC-1295: Mechanism and Research Overview
⚠️ Research Disclaimer: This content is for educational purposes only. All compounds discussed are research peptides. Consult a qualified healthcare professional before considering any protocol.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH). The version with Drug Affinity Complex (DAC) technology — CJC-1295 DAC — is designed to bind to serum albumin after injection, dramatically extending its half-life from minutes (for native GHRH) to approximately 6–8 days.

Drug Affinity Complex (DAC) Technology

The DAC modification involves a reactive maleimide group that forms a covalent bond with the cysteine-34 position on serum albumin in the bloodstream. This binding protects the peptide from enzymatic degradation and creates a slow-release depot, enabling sustained GH pulses over an extended period.

Mechanism of Action

CJC-1295 activates GHRH receptors on pituitary somatotroph cells, triggering the synthesis and pulsatile release of growth hormone. Unlike GHRPs which operate through the ghrelin receptor, CJC-1295 works upstream, amplifying the natural GHRH signaling cascade.

Key Research Findings

A 2006 human clinical trial (Teichman et al.) demonstrated that a single injection of CJC-1295 DAC produced sustained increases in serum GH and IGF-1 levels for up to 6 days, with IGF-1 increases of 28–39% maintained for up to 28 days following multiple doses. This was a landmark finding for long-acting GHRH analogues.

Important Disclaimer

CJC-1295 is a research peptide and is not approved for human therapeutic use. This content is educational only.

Sources & Further Reading

Peer-reviewed clinical trial data and research publications underpinning this article. See our full research library.

  1. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91:799–805. Phase 1/2 Clinical Trial